<DOC>
	<DOCNO>NCT02964104</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) insulin 287 subject type 2 diabetes .</brief_summary>
	<brief_title>A Trial Investigating Safety , Tolerability , Pharmacokinetics ( Exposure Trial Drug Body ) Pharmacodynamics ( Effect Investigated Drug Body ) Insulin 287 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Male female , age 18 64 year ( inclusive ) time sign informed consent . Subject consider generally healthy ( exception condition associate diabetes mellitus ) , base medical history , physical examination , result vital sign , ECG laboratory safety test , judge investigator . Body mass index 20.0 34.9 kg/m^2 ( inclusive ) . Type 2 diabetes mellitus ( diagnose clinically ) ≥12 month ( 365 day ) . No change insulin treatment regimen last 90 day prior screen . Current total daily insulin treatment 0.3 1.0 ( I ) U/kg/day ( inclusive ) . Known suspected hypersensitivity trial product relate product . Female pregnant , breastfeeding , intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require regulation practice ) ( highly effective contraceptive method consider failure rate le 1 % undesired pregnancy per year include surgical sterilisation , hormonal intrauterine device ( coil ) , oral hormonal contraceptive , sexual abstinence surgically sterilise partner ) . Females postmenopausal participate study use adequate contraceptive method . Postmenopausal define woman age &lt; 52 year amenorrheic one year serum follicle stimulate hormone ( FSH level &gt; 40 IU/L age ≥ 52 year amenorrheic less one year serum FSH level &gt; 40 IU/L age ≥ 52 year amenorrheic one year . Receipt investigational medicinal product within 3 month screen visit trial . History deep leg vein thrombosis repeat episode deep leg vein thrombosis 1st degree relative ( parent , sibling child ) judge investigator . Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event within past 180 day ) hypoglycaemic unawareness judge investigator hospitalisation diabetic ketoacidosis within past 180 day . Use oral antidiabetic drug ( OADs ) GLP1 receptor agonist ( e.g . exenatide , liraglutide ) within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>